Clear Harbor Asset Management’s Mereo BioPharma MREO Stock Holding History

Clear Harbor Asset Management’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.1K	Sell	32,000 -3,000	-9%	-$900	﹤0.01%	450
2026 Q1	$11.6K	Hold	35,000	–	–	﹤0.01%	449
2025 Q4	$14.6K	Sell	35,000 -42,000	-55%	-$79.9K	﹤0.01%	443
2025 Q3	$159K	Buy	77,000 +35,000	+83%	+$64.5K	0.01%	402
2025 Q2	$114K	Hold	42,000	–	–	0.01%	398
2025 Q1	$94.5K	Hold	42,000	–	–	0.01%	389
2024 Q4	$147K	Sell	42,000 -1,500	-3%	-$5.89K	0.01%	361
2024 Q3	$179K	Hold	43,500	–	–	0.01%	341
2024 Q2	$157K	Sell	43,500 -2,500	-5%	-$8.1K	0.01%	340
2024 Q1	$152K	Sell	46,000 -13,754	-23%	-$46.6K	0.01%	344
2023 Q4	$108K	Sell	59,754 -4,000	-6%	-$7.65K	0.01%	350
2023 Q3	$82.2K	Buy	63,754 +7,000	+12%	+$9.29K	0.01%	333
2023 Q2	$74.9K	Sell	56,754 -24,000	-30%	-$27.8K	0.01%	343
2023 Q1	$57.1K	Sell	80,754 -3,246	-4%	-$2.92K	0.01%	376
2022 Q4	$63K	Sell	84,000 -61,000	-42%	-$50.1K	0.01%	348
2022 Q3	$125K	Sell	145,000 -17,000	-10%	-$20.8K	0.02%	333
2022 Q2	$186K	Buy	162,000 +138,500	+589%	+$107K	0.02%	331
2022 Q1	$26K	Buy	23,500 +6,500	+38%	+$8.41K	﹤0.01%	395
2021 Q4	$27K	Buy	+17,000	New	+$34K	﹤0.01%	411

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Clear Harbor Asset Management's MREO Position: Q2 2026 in Review

Clear Harbor Asset Management reduced its Mereo BioPharma (MREO) stake by 8.6% in Q2 2026, selling an estimated $900 and leaving 32,000 shares worth $10.1K. The position accounts for ﹤0.01% of the portfolio, ranked #450.

Clear Harbor Asset Management first reported a position in MREO in Q4 2021 and has held it in 19 quarters since. The position peaked at $186K in Q2 2022. 61 funds tracked by Wall St. Rank hold MREO as of Q2 2026.

Clear Harbor Asset Management held 32,000 shares of Mereo BioPharma worth $10.1K as of Q2 2026.
Clear Harbor Asset Management sold 3,000 Mereo BioPharma shares in Q2 2026, an estimated $900.
Mereo BioPharma made up ﹤0.01% of Clear Harbor Asset Management's portfolio in Q2 2026, its #450 holding.
Clear Harbor Asset Management first reported a position in Mereo BioPharma in Q4 2021 and has held it in 19 quarters since.
Clear Harbor Asset Management's Mereo BioPharma position peaked at $186K in Q2 2022.
61 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2026.

Based on Clear Harbor Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.